StratDeck

Two stocks in Healthcare

Genmab A/S vs Gerresheimer: profit, growth, debt and price compared

Genmab A/S is stronger on 5 of 6 figures: profit margin, sales growth, debt, analysts' view and price trend. Gerresheimer is stronger on 1: price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore Genmab A/S' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Genmab A/S and Gerresheimer side by side
Genmab A/SGMAB.COGerresheimerGXI.DE
Net marginStronger: 17.0%−17.5%
Revenue growth, past yearStronger: +16.10%−0.80%
Debt to equityStronger: 82.1%236.7%
Forward P/E29.9×Stronger: 13.5×
Dividend yield——
AnalystsStronger: Strong buy · 13Hold · 12
From its 200-day averageStronger: +54.9%+13.7%

Share price over the past year

  • Genmab A/S+78.6%
  • Gerresheimer+40.9%

20 Nov 202518 Nov 2026

Genmab A/S or Gerresheimer: which is stronger?

  • GMAB.CO

    Which is more profitable?

    Genmab A/S keeps more of each sale as profit: 17.0% against −17.5%.

  • GMAB.CO

    Which is growing its sales faster?

    Genmab A/S is growing its sales faster: +16.10% over the past year, against −0.80%.

  • GMAB.CO

    Which has borrowed less?

    Genmab A/S has borrowed less: its debt is 82.1% of what its shareholders own, against 236.7% for Gerresheimer.

  • GXI.DE

    Which costs less for the profit it is expected to make?

    Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 29.9×.

  • Which pays more in dividends?

    Neither pays a dividend.

  • GMAB.CO

    Which do analysts rate higher?

    Analysts are warmer on Genmab A/S: Strong buy, against Hold for Gerresheimer.

  • GMAB.CO

    Which is in the stronger price trend?

    Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 13.7% above.

What each company does

GMAB.COGenmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Reports results on 16 February 2027

GXI.DEGerresheimer

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.

Reports results on 25 November 2026

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.